AbCellera Biologics Inc.

ABCLNASDAQHealthcare● Active

$5.42

$-0.20(-3.56%)

Market Cap$1.7B

P/E Ratio—

52W High$6.79

52W Low$2.33

Avg Volume5.9M

Open$5.86

Beta1.18

Free Cash Flow Financials Revenue

AbCellera Biologics Inc. (ABCL) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ABCL · free cash flow · updated Jun 8, 2026

Core FCF metrics

ABCL · FCF · TTM · margin & CAGR

Free cash flow was −$174.1M for FY2025 (fiscal year ending 2025-12-31), up 6.9% year-over-year The FCF margin was -231.7%.

FY2025 Free Cash Flow−$174.1M▲ +6.9% YoY

Trailing 12M (TTM)−$189.2Mtrailing 4 quarters sum

FCF Margin-231.7%−$174.1M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ABCL · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$131.3M(43M)−$174.1M▲ +6.9%-231.7%

FY2024−$108.6M(78M)−$187.0M▼ 54.0%-648.4%

FY2023−$43.9M(78M)−$121.4M▼ 159.3%-319.2%

FY2022$277.4M(73M)$204.7M▲ +10.0%42.2%

FY2021$244.6M(58M)$186.1M▲ +2221.7%49.6%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ABCL · P/FCF · FCF yield · FCF per share

AbCellera Biologics Inc. (ABCL) reported negative free cash flow of −$0.17B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

ABCL · cash flow statement · operating / investing / financing

For FY2025, AbCellera Biologics Inc. generated −$131.3M in operating cash flow and spent 43M in capital expenditures, yielding −$174.1M in free cash flow.

Operating Activities

−$131.3M

Cash from core business operations

2025-12-31

Investing Activities

+$87.8M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$14.1M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$131.3M) − |CapEx| (43M) = FCF (−$174.1M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ABCL vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

AbCellera Biologics Inc.YOU

ABCL

−$174.1M+6.9%-231.7%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

AbCellera Biologics Inc. (ABCL) reported free cash flow of −$174.1M for FY2025 (fiscal year ending 2025-12-31), up 6.9% year-over-year. The FCF margin was -231.7%.

Based on available data, AbCellera Biologics Inc. has maintained positive free cash flow for at least 3 fiscal year(s). FCF peaked at $204.7M in FY2022.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ABCL free cash flow · 8 questions

AbCellera Biologics Inc. free cash flow was −$174.1M for FY2025, up 6.9% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$189.2M.

ABCL free cash flowABCL FCFABCL FCF 2025ABCL free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · AbCellera Biologics Inc. · AbCellera Biologics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026